Companies › Acumen Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| sabirnetug anti-amyloid-beta protofibrils monoclonal antibody | APP | Phase 2 | Alzheimer Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06335173 | sabirnetug | Phase 2 | Alzheimer Disease | Neurology | Oct 2026 |
Cash and short-term investments of $79m on 2026-09-30; operating cash outflow about $92m a year; runway about 10 months at that burn, to Aug 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Alnylam Pharmaceuticals Roche Eli Lilly Eisai JYAMS PET Research & Development Amyloid Solution HTA Nuravax
Abcuro Tiziana Life Sciences Keros Therapeutics JYAMS PET Research & Development CytoDyn
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.